Lupin receives positive CHMP opinion for biosimilar Ranibizumab
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Clinical trial enrollment has long been a bottleneck in drug development
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
Subscribe To Our Newsletter & Stay Updated